YANTAI, China, April 24, 2024 /PRNewswire/ -- On April 22, the 2024 Radiopharmaceutical Innovation and Development Conference was successfully held in Beijing. The theme of the conference is "Creating a New Future for Drug Radiotherapy Development", which is hosted by the China Isotope and Radiation Industry Association. More than 300 guests from industry authorities, research institutes, universities, medical institutions and industry leaders attended the conference to share and exchange the latest research results and application progress of radiopharmaceuticals at home and abroad. Dongcheng Pharmaceutical Group, Novartis China, Hengrui Pharmaceutical, Yunnan Baiyao and other pharmaceutical companies jointly supported the conference to promote the development of China's nuclear medicine industry.
During the meeting, the China Isotope and Radiation Industry Association established the Radiopharmaceuticals Branch and held the first meeting of the first council of the branch. The first council of the radiopharmaceutical branch of the association elected Kong Fanpu as the chairman of the branch, Sun Piaoyang, Luo Zhifu, Du Jin, Zhang Ning, Yang Zhi, Zhu Zhaohui, Zhang Jinming, Luo Zhigang, Sui Yanying, Luo Ya, Li Jianguo, Zou Pei, Zhong Wenjing and other 13 people as vice presidents of the branch, and Huang Wei as the secretary general.
At the meeting, Wang Guangji and Dong Jiahong, academicians of the Chinese Academy of Engineering, Zhao Hongwei, academician of the Chinese Academy of Sciences, Tian Jiahe, chief physician of the First Medical Center of the Chinese People's Liberation Army General Hospital, Luo Zhifu, chief scientist of China National Nuclear Corporation, Zhang Lianshan, director and deputy general manager of Jiangsu Hengrui Pharmaceutical Co., Ltd., Zhang Ning, chief scientist of Yunnan Baiyao Group Co., Ltd., Yang Zhi, director of the Department of Nuclear Medicine of Peking University Cancer Hospital, etc., focused on medical isotopes, innovative drugs, RDC drugs, clinical transformation, non-clinical evaluation, Cutting-edge hot topics such as industrialization, shared and demonstrated the latest progress and achievements in the field of radiopharmaceuticals. Wang Suohui, Executive Vice President of the Association, Deputy Secretary of the Party Committee and General Manager of China Baoyuan Investment Co., Ltd., Kong Fanpu, Chairman of the Radiopharmaceutical Branch of the Association and Chief Researcher of Tsinghua University, Zhang Junqi, Secretary of the Party Committee and Chairman of China Tongsheng Co., Ltd., Luo Zhigang, Vice Chairman of the Association and General Manager of Yantai Dongcheng Pharmaceutical Group Co., Ltd., Zhang Jinming, Researcher of the First Medical Center of the Chinese People's Liberation Army General Hospital, and Zou Pei, Deputy Director of Jiangsu Institute of Atomic Medicine, presided over each link of the conference.
General Manager Luo Zhigang presided over the stage meeting
Ms. Liu Yan, Chief Medical Officer of Midu (Nanjing) Biotechnology Co., Ltd., delivered a keynote report entitled "Deep Image Analysis Empowering New Drug Development" at the conference. The report explained in depth the unique advantages of molecular imaging technology in the preclinical trials and clinical trials of drug development, as well as the service advantages of Midu Biotech in this stage.
At the same time, an exhibition of radiopharmaceutical-related products was held at the same time, and Dongcheng Pharmaceutical set up a booth to share and exchange the latest business and research results, which was widely recognized and concerned.
In recent years, a series of policies and measures have been introduced by the state, which have pointed out the direction and provided a strong guarantee for the innovation and development of the radiopharmaceutical industry. Under the leadership of the competent department of the industry, with the joint efforts of industry experts, enterprises and institutions, the mainland radiopharmaceutical industry has entered a stage of rapid development. As a "heparin expert and nuclear medicine pioneer", Dongcheng Pharmaceutical will adhere to strategic guidance and innovation-driven, and contribute to improving the R&D capabilities and innovation level of radiopharmaceuticals in mainland China and promoting the high-quality development of the radiopharmaceutical industry.